Skip to main content
OpenTrials
Completed

NCT Number: NCT00346008

Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Melanoma (Skin) Melanoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Iceland Genomics Corporation

Reykjavik, 105, Iceland

About this study

OBJECTIVES:

  • Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
  • Assess the feasibility of mutation detection using sequencing and HPLC.
  • Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.

OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

DISEASE CHARACTERISTICS:

  • Patients diagnosed with melanoma and selected family members are eligible to participate
  • Must live in Iceland

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified

Treatment and study plan

mutation analysis

Genetic

high performance liquid chromatography

Other

laboratory biomarker analysis

Other

Questionnaire Administration

Other

Primary outcomes

  1. Feasibility to identify melanoma

  2. Feasibility to detect mutation

  3. Ability to create datasets

Sponsors and collaborators

Lead sponsor

Iceland Genomics Corporation

Industry

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Genetic Epidemiologic Studies of Melanoma in Iceland

Important dates

Study start
2005
Primary completion
2008
Study completion
2009
First posted
Jun 29, 2006
Registry last updated
May 30, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.